Allergan, Inc., the #1 Global Medical Aesthetics Company, and Clinique, the #1 Prestige Cosmetics Brand in the United States, Form Strategic Collaboration to Develop New Skin Care Line

Allergan, Inc. (NYSE:AGN) and Clinique Laboratories, LLC, today announced a strategic collaboration which combines Clinique’s expertise in product development and formulation with Allergan’s leadership in the medical aesthetics market. The new skin care line, which will incorporate the Clinique brand name, will offer clinically proven skin care products to complement in-office aesthetic procedures. It will be sold exclusively in physicians’ offices in the United States and is expected to launch in the fall of 2008. Over the past ten years, non-surgical aesthetic procedures have increased nearly 750 percent, with consumers in the United States spending more than $12 billion on cosmetic procedures in 20061. The top five non-surgical aesthetic treatments in 2006, administered in the physician’s office, included BOTOX® Cosmetic and hyaluronic acid dermal fillers such as JUVÉDERM™, laser hair removal, microdermabrasion and laser skin resurfacing. As more patients seek advice and treatments from aesthetic specialty physicians, there is a similar, growing trend of consumers purchasing skin care products in the physician’s office. Allergan and Clinique expect to pioneer a new category of best-in-class skin care products sold exclusively in physicians’ offices that will be Allergy Tested and 100% Fragrance Free. "In collaboration with Clinique, our goal is to establish a leadership position in physician-dispensed skin care by offering a one-stop approach to specialized skin care products under a brand name that is trusted by consumers and backed by science on which physicians can rely,” said David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer. "The collaboration combines Allergan’s leadership in medical aesthetics and our deep understanding of the physician channel based on our Total Facial Rejuvenation portfolio – including BOTOX® Cosmetic, JUVÉDERM™ and our skin care product line, with Clinique’s history of formulating leading consumer skin care products guided by dermatologists. Together with our complementary strengths, we expect Clinique and Allergan to grow this market.” "Clinique’s promise to our consumers has always been to create dermatologist guided, Allergy Tested, 100% Fragrance Free products that address skin care needs. Today we are entering a new phase of our relationship with the medical community,” said Lynne Greene, Global President, Clinique Laboratories. "By joining forces with Allergan, the number one medical aesthetics company, we are now able to service consumers who are under the care of a physician with this completely new class of products.” "Clinique’s rich dermatological heritage dates back 40 years,” said William P. Lauder, President and Chief Executive Officer, The Estée Lauder Companies Inc. "This new skin care line, created in collaboration with Allergan, is the next generation of the expression of Clinique’s unique position delivered through one of the fastest growing channels today, physicians’ offices.” As part of the agreement, Clinique will be responsible for formulating, developing and manufacturing the new product line. Clinique will sell products to Allergan while Allergan will record sales to physicians and handle consumer and professional marketing and distribution. The agreement with Clinique will allow Allergan to expand the size of its current sales force dedicated to physician-dispensed skin care. Clinique and Allergan may also conduct clinical trials and work with the physician community to ensure the success of the new skin care line. Important BOTOX® Cosmetic (Botulinum Toxin Type A) Information BOTOX® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe frown lines between the brows in people 18 to 65 years of age. Important BOTOX® Cosmetic (Botulinum Toxin Type A) Safety Information Serious heart problems and serious allergic reactions have been reported rarely. If you think you are having an allergic reaction or other unusual symptoms, such as difficulty swallowing, speaking or breathing, call your doctor immediately. The most common side effects following injection include temporary eyelid droop and nausea. Localized pain, infection, inflammation, tenderness, swelling, redness and/or bleeding/bruising may be associated with the injection. Patients with certain neuromuscular disorders such as ALS, myasthenia gravis or Lambert-Eaton syndrome may be at increased risk of serious side effects. For full prescribing information, please visit www.botoxcosmetic.com. Important JUVÉDERM™ Safety Information JUVÉDERM™ is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds), and is generally well tolerated. In clinical studies, adverse events were usually mild to moderate in nature, did not require intervention and lasted seven days or less. The most common side effects included temporary injection site reactions including redness, pain/tenderness, firmness, swelling, lumps and bumps and bruising. For complete patient safety and prescribing information, please visit www.Juvederm.com. About Allergan, Inc. (NYSE:AGN) Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential – to see more clearly, move more freely, express themselves more fully. The Company employs more than 7,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries. About Clinique Introduced in 1968, Clinique was the first ever dermatologist-created, prestige cosmetic brand. Clinique’s mission has always been to provide the highest quality and most effective line of products to enhance every skin type and tone. The brand’s customized approach and quality products – all meticulously tested and carefully formulated with the latest science – have made Clinique one of the leading skin care authorities in the world. All makeup and skin care products are Allergy Tested and 100% Fragrance Free. Clinique offers products for men and women of all ages and ethnicities. Clinique is sold in more than 135 countries and territories, 17,000 sales locations and on www.clinique.com. About the The Estée Lauder Companies Inc. (NYSE:EL) Founded in 1946, The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 135 countries and territories under well-recognized brand names, including Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, M•A•C, Bobbi Brown, Tommy Hilfiger, La Mer, Donna Karan, Aveda, Jo Malone, Bumble and bumble, Darphin, Michael Kors, American Beauty, Flirt!, Good Skin™, Grassroots, Sean John, Missoni, Daisy Fuentes, Tom Ford Beauty, Mustang, Coach and Ojon. Allergan and The Estée Lauder Companies Inc. Forward-Looking Statements This press release contains "forward-looking statements,” including the statements by Mr. Pyott, Mr. Lauder and Ms. Greene and other statements regarding the market potential associated with the new product line. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan’s or The Estée Lauder Companies Inc.’s expectations and projections. Risks and uncertainties include, among other things, general industry and professional skin care channel conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new skin care products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing new products; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. Allergan and the The Estée Lauder Companies Inc. expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan’s public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors” in Allergan’s 2006 Form 10-K and Allergan’s Form 10-Q for the quarter ended September 28, 2007. Copies of Allergan’s press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling (714) 246-4636. Additional information concerning these and other risk factors can also be found in press releases issued by The Estée Lauder Companies Inc., as well as in its filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors” in The Estée Lauder Companies Inc. Form 10-K for the fiscal year ended June 30, 2007. Copies of The Estée Lauder Companies Inc. press releases, filings as well as additional information about the company, are available at www.elcompanies.com or you can contact The Estée Lauder Companies Inc. Investor Relations Department by calling (212) 572-4184. Allergan, JUVÉDERM™ and BOTOX® Cosmetic are marks owned by Allergan, Inc. The other trademarks in this press release are owned or licensed by subsidiaries of The Estée Lauder Companies Inc. 1 American Society for Aesthetic Plastic Surgery (ASAPS), 2006 Statistics on Cosmetic Surgery, www.surgery.org (January 24, 2008)